407 related articles for article (PubMed ID: 18991651)
1. Regulation of iron absorption in hemoglobinopathies.
Rechavi G; Rivella S
Curr Mol Med; 2008 Nov; 8(7):646-62. PubMed ID: 18991651
[TBL] [Abstract][Full Text] [Related]
2. Alpha- and Beta-thalassemia: Rapid Evidence Review.
Baird DC; Batten SH; Sparks SK
Am Fam Physician; 2022 Mar; 105(3):272-280. PubMed ID: 35289581
[TBL] [Abstract][Full Text] [Related]
3. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
Rivella S; May C; Chadburn A; Rivière I; Sadelain M
Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
5. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
[TBL] [Abstract][Full Text] [Related]
6. Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.
Di Paola A; Marrapodi MM; Di Martino M; Giliberti G; Di Feo G; Rana D; Ahmed S; Argenziano M; Rossi F; Roberti D
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474150
[TBL] [Abstract][Full Text] [Related]
7. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
8. Management of iron overload in hemoglobinopathies.
Allali S; de Montalembert M; Brousse V; Chalumeau M; Karim Z
Transfus Clin Biol; 2017 Sep; 24(3):223-226. PubMed ID: 28673501
[TBL] [Abstract][Full Text] [Related]
9. Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?
Evangelidis P; Venou TM; Fani B; Vlachaki E; Gavriilaki E;
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003451
[TBL] [Abstract][Full Text] [Related]
10. Physiology and pathophysiology of iron in hemoglobin-associated diseases.
Coates TD
Free Radic Biol Med; 2014 Jul; 72():23-40. PubMed ID: 24726864
[TBL] [Abstract][Full Text] [Related]
11. [Results of hematopoietic stem cell transplantation in hemoglobinopathies: thalassemia major and sickle cell disease].
Hladun R; Elorza I; Olivé T; Dapena JL; Llort A; Sánchez de Toledo J; Díaz de Heredia C
An Pediatr (Barc); 2013 Aug; 79(2):75-82. PubMed ID: 23402775
[TBL] [Abstract][Full Text] [Related]
12. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
13. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
14. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies.
Jastaniah W; Harmatz P; Pakbaz Z; Fischer R; Vichinsky E; Walters MC
Pediatr Blood Cancer; 2008 Feb; 50(2):319-24. PubMed ID: 17557314
[TBL] [Abstract][Full Text] [Related]
15. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
16. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
17. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
[TBL] [Abstract][Full Text] [Related]
18. Manipulation of Developmental Gamma-Globin Gene Expression: an Approach for Healing Hemoglobinopathies.
Venkatesan V; Srinivasan S; Babu P; Thangavel S
Mol Cell Biol; 2020 Dec; 41(1):. PubMed ID: 33077498
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy in thalassemia and hemoglobinopathies.
Breda L; Gambari R; Rivella S
Mediterr J Hematol Infect Dis; 2009 Nov; 1(1):e2009008. PubMed ID: 21415990
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for hemoglobinopathies: progress and challenges.
Dong A; Rivella S; Breda L
Transl Res; 2013 Apr; 161(4):293-306. PubMed ID: 23337292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
